Drug Trial Radar · NCT06195228
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Jan 1, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking Union Medical College Hospital; Shanxi Province Cancer Hospital; Henan Cancer Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Zhejiang Cancer Hospital; The Affiliated Hospital of Inner Mongolia Medical University; Ruijin Hospital; Fujian Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shanghai 6th People's Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Shanghai 10th People's Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Changhai Hospital; Tianjin Medical University Cancer Institute and Hospital; Jiangsu Cancer Institute & Hospital; The First Affiliated Hospital of Anhui University of Chinese Medicine; Hunan Provincial People's Hospital; Dalian Friendship Hospital Affiliated to Dalian Medical University; The Third Affiliated Hospital of Soochow University; Sun Yat-sen University; Liaoning Cancer Hospital & Institute; Sir Run Run Shaw Hospital
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
Conditions
- Advanced Thyroid Cancer Patients Who Received Target Therapy
Interventions
dabrafenib plus trametinib with or without PD-1 antibodyDrug
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoyDrug
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoyDrug
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibodyDrug
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibodyDrug
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the targetDrug
Advanced thyroid cancer patients who had other treatment targets not included above
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR)Time frame: up to approximately 3 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Peking union medical college hospital
Beijing, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Caixia Liu
Hohhot, Inner Mongolia, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Shanxi, Taiyuan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.